[{"symbol": "MDGL", "price": 501.68, "beta": -1.014, "volAvg": 356054, "mktCap": 11393855152, "lastDiv": 0, "range": "265-615", "changes": 5.8, "companyName": "Madrigal Pharmaceuticals, Inc.", "currency": "USD", "cik": "0001157601", "isin": "US5588681057", "cusip": "558868105", "exchange": "NASDAQ Global Select", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.madrigalpharma.com", "description": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-\u00df agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.", "ceo": "William J. Sibold", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "528", "phone": "267 824 2827", "address": "Four Tower Bridge", "city": "West Conshohocken", "state": "PA", "zip": "19428", "dcfDiff": 337.30267, "dcf": 164.3773300452337, "image": "https://images.financialmodelingprep.com/symbol/MDGL.png", "ipoDate": "2007-02-06", "defaultImage": false, "isEtf": false, "isActivelyTrading": true, "isAdr": false, "isFund": false}]